Tvardi Therapeutics
TVRD
42 hedge funds and large institutions have $160M invested in Tvardi Therapeutics in 2014 Q1 according to their latest regulatory filings, with 42 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCP
Rho Capital Partners
New York
|
+$43.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.6M |
| 3 |
LBG
Lloyds Banking Group
London,
United Kingdom
|
+$14.6M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$10.7M |
| 5 |
JP Morgan Chase
New York
|
+$5.99M |
Top Sellers
TVRD Hedge Fund Activity: Q1 2014 in Review
42 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2014, worth a combined $160M.
Buyers outnumbered sellers: 42 funds opened new TVRD positions and 0 closed out — a net gain of 42 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Rho Capital Partners, opening a new position worth an estimated $43.8M.
- 42 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $160M of Tvardi Therapeutics stock for Q1 2014.
- 42 funds opened new Tvardi Therapeutics positions in Q1 2014 and 0 closed out, a net change of +42 holders.
- The largest Tvardi Therapeutics buyer in Q1 2014 was Rho Capital Partners, an estimated $43.8M added.
Based on aggregated 13F filings for Q1 2014.